# Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors

> **NCT02756845** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 15 (actual)

## Conditions studied

- Advanced Non CNS Tumors

## Interventions

- **DRUG:** Talimogene Laherparepvec

## Key facts

- **NCT ID:** NCT02756845
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-16
- **Primary completion:** 2022-01-17
- **Final completion:** 2022-11-29
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02756845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02756845, "Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02756845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*